comparemela.com

Latest Breaking News On - Insider transactions at regeneron pharmaceuticals - Page 12 : comparemela.com

Penbrook Management LLC Reduces Holdings in Regeneron Pharmaceuticals, Inc (NASDAQ:REGN)

Penbrook Management LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 4.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,022 shares of the biopharmaceutical company’s stock after selling 50 shares during […]

Quarry LP Boosts Holdings in Regeneron Pharmaceuticals, Inc (NASDAQ:REGN)

Quarry LP boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 106.7% during the first quarter, Holdings Channel.com reports. The institutional investor owned 674 shares of the biopharmaceutical company’s stock after buying an additional 348 shares during the period. Quarry LP’s holdings in Regeneron Pharmaceuticals were worth $554,000 as of […]

Moore Capital Management LP Makes New $8 22 Million Investment in Regeneron Pharmaceuticals, Inc (NASDAQ:REGN)

Moore Capital Management LP bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $8,217,000. Several other […]

Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,050 00 Price Target at Oppenheimer

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price raised by Oppenheimer from $950.00 to $1,050.00 in a research report report published on Monday morning, MarketBeat reports. Oppenheimer currently has a market perform rating on the biopharmaceutical company’s stock. REGN has been the subject of several other reports. Guggenheim decreased their price target on […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.